Literature DB >> 31287369

Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Worth Longest1,2, Benjamin Spence1, Michael Hindle2.   

Abstract

Nebulizers have a number of advantages for the delivery of inhaled pharmaceutical aerosols, including the use of aqueous formulations and the ability to deliver process-sensitive proteins, peptides, and biological medications. A frequent disadvantage of nebulized aerosols is poor lung delivery efficiency, which wastes valuable medications, increases delivery times, and may increase side effects of the medication. A focus of previous development efforts and previous nebulizer reviews, has been an improvement of the underlying nebulization technology controlling the breakup of a liquid into droplets. However, for a given nebulization technology, a wide range of secondary devices and strategies can be implemented to significantly improve lung delivery efficiency of the aerosol. This review focuses on secondary devices and technologies that can be implemented to improve the lung delivery efficiency of nebulized aerosols and potentially target the region of drug delivery within the lungs. These secondary devices may (1) modify the aerosol size distribution, (2) synchronize aerosol delivery with inhalation, (3) reduce system depositional losses at connection points, (4) improve the patient interface, or (5) guide patient inhalation. The development of these devices and technologies is also discussed, which often includes the use of computational fluid dynamic simulations, three-dimensional printing and rapid prototype device and airway model construction, realistic in vitro experiments, and in vivo analysis. Of the devices reviewed, the implementation of streamlined components may be the most direct and lowest cost approach to enhance aerosol delivery efficiency within nonambulatory nebulizer systems. For applications involving high-dose medications or precise dose administration, the inclusion of active devices to control aerosol size, guide inhalation, and synchronize delivery with inhalation hold considerable promise.

Entities:  

Keywords:  inhalers; nebulizers; pharmaceutical aerosol devices; respiratory drug delivery

Mesh:

Substances:

Year:  2019        PMID: 31287369      PMCID: PMC6781258          DOI: 10.1089/jamp.2018.1508

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  115 in total

1.  Omron NE U22: Comparison between vibrating mesh and jet nebulizer.

Authors:  Shibu Skaria; Gerald C Smaldone
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-06       Impact factor: 2.849

Review 2.  Recent advances in predictive understanding of respiratory tract deposition.

Authors:  Warren H Finlay; Andrew R Martin
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2008-06       Impact factor: 2.849

3.  Improving the lung delivery of nasally administered aerosols during noninvasive ventilation-an application of enhanced condensational growth (ECG).

Authors:  P Worth Longest; Geng Tian; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-16       Impact factor: 2.849

Review 4.  Imaging in Aerosol Medicine.

Authors:  Timothy E Corcoran
Journal:  Respir Care       Date:  2015-06       Impact factor: 2.258

5.  Comparative Study on the Size Distributions, Respiratory Deposition, and Transport of Particles Generated from Commonly Used Medical Nebulizers.

Authors:  Yang Wang; Jiayu Li; Anna Leavey; Caroline O'Neil; Hilary M Babcock; Pratim Biswas
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-12-15       Impact factor: 2.849

Review 6.  The function and performance of aqueous aerosol devices for inhalation therapy.

Authors:  Thiago C Carvalho; Jason T McConville
Journal:  J Pharm Pharmacol       Date:  2016-04-08       Impact factor: 3.765

Review 7.  Clinical Controversies in Aerosol Therapy for Infants and Children.

Authors:  Robert M DiBlasi
Journal:  Respir Care       Date:  2015-06       Impact factor: 2.258

Review 8.  Aerosol therapy for children.

Authors:  B K Rubin; J B Fink
Journal:  Respir Care Clin N Am       Date:  2001-06

9.  Lung function in adult patients with cystic fibrosis after using the eFlow rapid for one year.

Authors:  Susanne Naehrig; S Lang; H Schiffl; R M Huber; R Fischer
Journal:  Eur J Med Res       Date:  2011-02-24       Impact factor: 2.175

Review 10.  Aerosol delivery to ventilated infant and pediatric patients.

Authors:  James B Fink
Journal:  Respir Care       Date:  2004-06       Impact factor: 2.258

View more
  5 in total

1.  Multiscale in silico lung modeling strategies for aerosol inhalation therapy and drug delivery.

Authors:  Pantelis Koullapis; Bo Ollson; Stavros C Kassinos; Josué Sznitman
Journal:  Curr Opin Biomed Eng       Date:  2019-11-13

Review 2.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

Review 3.  The future of inhalation therapy in chronic obstructive pulmonary disease.

Authors:  Mario Cazzola; Josuel Ora; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-02-17

4.  A whole lung in silico model to estimate age dependent particle dosimetry.

Authors:  Kamran Poorbahrami; Irene E Vignon-Clementel; Shawn C Shadden; Jessica M Oakes
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

Review 5.  Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.

Authors:  Carlos Cruz-Teran; Karthik Tiruthani; Morgan McSweeney; Alice Ma; Raymond Pickles; Samuel K Lai
Journal:  Adv Drug Deliv Rev       Date:  2020-12-09       Impact factor: 17.873

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.